BRIEF SUMMARY OF THE INVENTION
The invention relates to the use of proline and/or 4-hydroxyproline as therapeutic agents, especially for the treatment for wounds as well as inflammation and/or pain. The invention also relates to pharmaceutical compositions comprising proline and/or 4-hydroxyproline
FIELD OF THE INVENTION
The invention relates to a new aprepritant compositions and crystalline compounds containing aprepitant. More particularly, the invention relates to solvated aprepitant L-proline solvate compositions, aprepitant L-proline solvate cocrystals, therapeutic uses of the aprepitant
FIELD OF THE INVENTION
The invention relates to a new aprepitant composition and a crystalline compound containing aprepitant, more particularly, the invention relates to an aprepitant L-proline composition, an aprepitant L-proline cocrystal, therapeutic uses of the aprepitant L-proline or the
TECHNICAL FIELD
The present invention relates to novel cyclosporin analogues, compositions containing them, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention of organ transplantation rejection, the treatment of immune disorders and
FIELD OF THE INVENTION
Non-peptidic compounds are described for treatment of autoimmune diseases. Of particular interest are pipecolic acid derivatives compounds incorporating a characterizing segment condensed from pipecolic acid, aspartic acid, proline and threonine, or derivatives thereof, which
BACKGROUND OF THE INVENTION
This invention relates to methods for treating inflammatory diseases by administration of a thrombin inhibitor.
Anti-inflammatory drugs include non steroidal anti-inflammatory drugs (NSAIDs) which exert anti-inflammatory, analgesic and antipyretic activity. These include
BACKGROUND OF THE INVENTION
Complement anaphylatoxin C5a is a 74-amino acid peptide generated from the fifth component of complement (C5) during complement activation (Ember et al., Immunopharmacology 38:3, 1997; Gerard, Annu Rev Immunol. 12:775, 1994). C5a acts efficiently as an anaphylatoxin
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 371 National Phase Entry of International Patent Application No. PCT/EP2016/067090 filed on Jul. 18, 2016 which claims benefit under 35 U.S.C. .sctn. 119(b) of EP Application No. 15177013.8 filed Jul. 16, 2015 and EP Application No.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a new pharmaceutical composition useful for the treatment of pyrexia and inflammation. More particularly, this invention relates to a tripeptide sequence contained in alpha-Melanocyte Stimulating Hormone and ACTH which
1. FIELD OF THE INVENTION
This invention relates to a new pharmaceutical composition useful for the treatment of pyrexia and inflammation. More particularly, this invention relates to a tripeptide sequence contained in alpha-Melanocyte Stimulating Hormone and ACTH which has been identified as an
REFERENCE TO SEQUENCE LISTING
The present application incorporates by reference SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 provided herewith on a diskette, created on Jan. 11, 2005 and containing 5,979 bytes. The information recorded on the diskette is identical to the written
FIELD OF THE INVENTION
This invention concerns a new family of peptide molecules having the capacity especially of stimulating the expression of the cytokines of inflammation and promoting regeneration of tissues. The invention, thus, also pertains to pharmaceutical compositions containing at least
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of peptidyl derivatives of aromatic diesters of .alpha.-aminoalkylphosphonic acids useful for selectively inhibiting elastase, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting
TECHNICAL FIELD
The present invention relates to the fields of cancer treatment, inflammatory disease, and peptide chemistry.
BACKGROUND
The amino acid sequence Leu-pro-pro-ser-arg (SEQ ID NO:1) is a known immunostimulant and is described in papers by W. Weigle and is the subject of a US Patent.
BACKGROUND OF THE INVENTION
Diseases affecting the connective tissues of the body have been the subject of a great deal of investigation for the past two decades. The essential amino acid L-hydroxyproline is an important constituent of proteins, particularly those proteins comprising the connective
The most complete medicinal herbs database backed by science
Works in 55 languages
Herbal cures backed by science
Herbs recognition by image
Interactive GPS map - tag herbs on location (coming soon)
Read scientific publications related to your search
Search medicinal herbs by their effects
Organize your interests and stay up do date with the news research, clinical trials and patents
Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against. *All information is based on published scientific research